While GLP-1 agonists may produce greater total weight loss, AOD-9604 more selectively targets fat tissue while preserving muscle mass
Dosing began at 0.25 mg of each active drug and escalated every four weeks until the full 2.4 mg dose was reached by week 16
It is also used to manage vitamin B12 deficiencies resulting from specific surgeries, diseases of the stomach or gut, and any other genetic disorders affecting vitamin B12 metabolism
Versatile Across Experimental Designs : Researchers use the combination in protocols that track outcomes such as body weight, energy intake, glycemic measures, blood pressure, and other cardiometabolic markers (model-dependent)
Unusual tiredness or lack of energy Recurring neurological symptoms Inadequate improvement in overall well-being If you notice these signs, talk to your healthcare provider
Reconstitute using bacteriostatic water or laboratory-grade solvents appropriate to the assay